Alzamend Neuro (ALZN) Competitors $3.24 +0.05 (+1.57%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$3.20 -0.04 (-1.08%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALZN vs. CLDI, PHXM, ORGS, TLPH, CYCN, ERNA, APRE, TRAW, CTXR, and AEONShould you be buying Alzamend Neuro stock or one of its competitors? The main competitors of Alzamend Neuro include Calidi Biotherapeutics (CLDI), PHAXIAM Therapeutics (PHXM), Orgenesis (ORGS), Talphera (TLPH), Cyclerion Therapeutics (CYCN), Eterna Therapeutics (ERNA), Aprea Therapeutics (APRE), Traws Pharma (TRAW), Citius Pharmaceuticals (CTXR), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical products" industry. Alzamend Neuro vs. Its Competitors Calidi Biotherapeutics PHAXIAM Therapeutics Orgenesis Talphera Cyclerion Therapeutics Eterna Therapeutics Aprea Therapeutics Traws Pharma Citius Pharmaceuticals AEON Biopharma Alzamend Neuro (NASDAQ:ALZN) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, community ranking, earnings, media sentiment, dividends, risk and analyst recommendations. Does the MarketBeat Community prefer ALZN or CLDI? Alzamend Neuro received 7 more outperform votes than Calidi Biotherapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAlzamend NeuroOutperform Votes777.78% Underperform Votes222.22% Calidi BiotherapeuticsN/AN/A Do institutionals & insiders hold more shares of ALZN or CLDI? 49.6% of Alzamend Neuro shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 30.2% of Alzamend Neuro shares are owned by company insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer ALZN or CLDI? In the previous week, Alzamend Neuro had 4 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 4 mentions for Alzamend Neuro and 0 mentions for Calidi Biotherapeutics. Alzamend Neuro's average media sentiment score of 0.46 beat Calidi Biotherapeutics' score of 0.00 indicating that Alzamend Neuro is being referred to more favorably in the media. Company Overall Sentiment Alzamend Neuro Neutral Calidi Biotherapeutics Neutral Which has better valuation & earnings, ALZN or CLDI? Alzamend Neuro has higher earnings, but lower revenue than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlzamend NeuroN/AN/A-$9.95MN/AN/ACalidi Biotherapeutics$50K219.37-$29.22MN/AN/A Do analysts rate ALZN or CLDI? Alzamend Neuro currently has a consensus target price of $180.00, indicating a potential upside of 5,455.56%. Calidi Biotherapeutics has a consensus target price of $10.00, indicating a potential upside of 2,798.55%. Given Alzamend Neuro's higher probable upside, research analysts plainly believe Alzamend Neuro is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alzamend Neuro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ALZN or CLDI more profitable? Company Net Margins Return on Equity Return on Assets Alzamend NeuroN/A N/A -289.14% Calidi Biotherapeutics N/A N/A -344.45% Which has more volatility & risk, ALZN or CLDI? Alzamend Neuro has a beta of -0.28, meaning that its share price is 128% less volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. SummaryAlzamend Neuro beats Calidi Biotherapeutics on 8 of the 10 factors compared between the two stocks. Get Alzamend Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for ALZN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALZN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALZN vs. The Competition Export to ExcelMetricAlzamend NeuroPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.60M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E RatioN/A8.4326.6319.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book-0.926.536.964.60Net Income-$9.95M$143.25M$3.23B$248.06M7 Day Performance-10.50%-0.06%-1.13%-0.94%1 Month Performance-15.84%11.77%8.59%3.52%1 Year Performance-92.08%3.66%33.63%14.02% Alzamend Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALZNAlzamend Neuro2.8762 of 5 stars$3.24+1.6%$180.00+5,455.6%-93.6%$2.60MN/A0.004News CoverageAnalyst UpgradeShort Interest ↑CLDICalidi Biotherapeutics1.5053 of 5 stars$0.34+2.4%$10.00+2,876.2%N/A$10.68M$50K0.0038PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049News CoverageORGSOrgenesis1.5478 of 5 stars$2.20-3.1%N/AN/A$10.56M$662K0.00150Gap UpTLPHTalphera2.2864 of 5 stars$0.51-2.0%$5.00+890.1%-49.0%$10.35M$27K-0.7319Positive NewsCYCNCyclerion Therapeutics1.6683 of 5 stars$3.22+2.5%N/A+51.7%$10.34M$2.08M-2.7830ERNAEterna Therapeutics0.918 of 5 stars$0.16-13.2%N/A-92.3%$10.29M$535K-0.0210Stock SplitShort Interest ↓Gap DownAPREAprea Therapeutics3.225 of 5 stars$1.86+1.1%$15.50+733.3%-55.3%$10.29M$580K-0.667Positive NewsShort Interest ↑Gap DownTRAWTraws Pharma0.6847 of 5 stars$1.81+8.7%N/AN/A$10.03M$227K-0.0117Short Interest ↑CTXRCitius Pharmaceuticals2.3754 of 5 stars$1.02-25.9%$54.50+5,269.5%-94.4%$9.97MN/A0.0020Gap DownHigh Trading VolumeAEONAEON Biopharma2.6654 of 5 stars$0.88+0.3%$360.00+41,042.9%-99.1%$9.89MN/A4.865Negative NewsShort Interest ↑Gap Down Related Companies and Tools Related Companies Calidi Biotherapeutics Competitors PHAXIAM Therapeutics Competitors Orgenesis Competitors Talphera Competitors Cyclerion Therapeutics Competitors Eterna Therapeutics Competitors Aprea Therapeutics Competitors Traws Pharma Competitors Citius Pharmaceuticals Competitors AEON Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALZN) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alzamend Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alzamend Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
